ImmunityBio (NASDAQ: IBRX) has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Anktiva (nogapendekin alfa inbakicept-pmln) combined with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) who have papillary-only disease, without carcinoma in situ (CIS). The FDA has set a target action date of January 6, 2027.
The application seeks to expand Anktiva's current approved indication, which is limited to BCG-unresponsive NMIBC with CIS, including cases with or without papillary tumors. The company estimates that approximately 85% of the roughly 64,000 U.S. patients diagnosed with NMIBC each year have papillary disease, representing a significantly larger patient population.
Clinical Data and Trial Results
The sBLA is supported by data from Cohort B of the QUILT 3.032 Phase 2/3 clinical trial, which enrolled 80 patients with high-grade, papillary-only disease. The study met its primary endpoint, reporting a 12-month disease-free survival (DFS) rate of 58.2%. DFS measures the proportion of patients who remain free from cancer recurrence or progression during the specified period.
ImmunityBio founder Dr. Patrick Soon-Shiong emphasized the limited treatment options available for patients with this specific disease subtype. CEO Richard Adcock described the FDA filing as an "important milestone" and noted that papillary-only disease represents the "larger segment" among BCG-unresponsive cases.
Competitive Landscape
Anktiva faces competition from established therapies. Merck's Keytruda (pembrolizumab) is approved for certain BCG-unresponsive high-risk NMIBC patients with CIS. Johnson & Johnson's Inlexzo (formerly TAR-200) received FDA approval in 2025 for BCG-unresponsive cases with CIS, and can be used regardless of whether papillary tumors are present. ImmunityBio recently presented data at the American Urological Association meeting, including indirect comparisons of Anktiva plus BCG against nadofaragene firadenovec (Ferring's Adstiladrin) and TAR-200. Dr. Brooke B. Edwards from The Urology Group in Cincinnati noted these findings could aid in shared decision-making, though the company acknowledged the analyses were not head-to-head trials.
Financial Performance and Supply Agreement
ImmunityBio reported first-quarter net product revenue of $44.2 million, a 168% increase year-over-year. However, the company's net loss widened sharply to $632.8 million, primarily due to changes in the fair value of warrants, derivatives, and related-party note liabilities. As of the end of the quarter, the company held $380.9 million in cash, cash equivalents, and marketable securities.
In a May 18 securities filing, ImmunityBio disclosed an exclusive development and supply agreement with Japan BCG Laboratory for the Tokyo-172 BCG strain in the U.S. and its territories. No payment is required before FDA approval, and the agreement runs for 10 years from the date of approval.
Regulatory and Market Risks
The FDA's acceptance of the application does not guarantee approval. The agency will evaluate whether papillary disease is sufficiently similar to CIS to extrapolate data from the existing label. The FDA has previously raised concerns about single-arm studies in patients with only papillary disease. Potential outcomes include a limited label, extended review, or outright denial.
Adding to the regulatory uncertainty, the FDA sent a warning letter to ImmunityBio in March regarding what it deemed false or misleading promotion of Anktiva. Piper Sandler analyst Edward Tenthoff expressed confidence that the company could address the FDA's concerns and maintained his revenue forecast.
ImmunityBio shares closed at $7.76, down 2.8% ahead of the announcement, giving the company a market capitalization of approximately $8.0 billion. The next fixed milestone is the January 6, 2027 PDUFA date, with the market balancing the potential for a larger bladder cancer market against ongoing regulatory and competitive challenges.
